Corcept Therapeutics Incorporated
US ˙ NasdaqCM ˙ US2183521028

SecurityCORT / Corcept Therapeutics Incorporated
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership13,090 shares
Latest Disclosed Value $ 960,806
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series reports 90.50% decrease in ownership of CORT / Corcept Therapeutics Incorporated

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 13,090 shares of Corcept Therapeutics Incorporated (US:CORT) valued at $960,806 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 137,801 shares of Corcept Therapeutics Incorporated. This represents a change in shares of -90.50% during the quarter. The current value of the position is $950,596 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Corcept Therapeutics EC US2183521028 13,090 -124,711 -90.50 961 -93.90 0.0216
2025-05-28 2025-03-31 NP Corcept Therapeutics EC US2183521028 137,801 1,463 1.07 15,740 129.10 0.3775
2025-02-25 2024-12-31 NP Corcept Therapeutics EC US2183521028 136,338 -22,352 -14.09 6,870 -6.45 0.1500
2024-11-26 2024-09-30 NP Corcept Therapeutics EC US2183521028 158,690 4,840 3.15 7,344 46.94 0.1389
2024-08-26 2024-06-30 NP Corcept Therapeutics EC US2183521028 153,850 12,465 8.82 4,999 40.35 0.1018
2024-05-28 2024-03-31 NP Corcept Therapeutics EC US2183521028 141,385 -4,749 -3.25 3,561 -24.97 0.0743
2024-02-26 2023-12-31 NP Corcept Therapeutics EC US2183521028 146,134 10,041 7.38 4,746 28.03 0.1013
2023-11-28 2023-09-30 NP Corcept Therapeutics EC US2183521028 136,093 -2,849 -2.05 3,708 19.93 0.0967
2023-08-25 2023-06-30 NP Corcept Therapeutics EC US2183521028 138,942 1,817 1.33 3,091 4.07 0.0733
2023-05-26 2023-03-31 NP Corcept Therapeutics EC US2183521028 137,125 2,593 1.93 2,970 8.71 0.0791
2023-02-24 2022-12-31 NP Corcept Therapeutics EC US2183521028 134,532 -805 -0.59 2,732 -21.27 0.0752
2022-11-25 2022-09-30 NP Corcept Therapeutics EC US2183521028 135,337 3,605 2.74 3,470 10.79 0.0994
2022-08-25 2022-06-30 NP Corcept Therapeutics EC US2183521028 131,732 -1,377 -1.03 3,133 4.50 0.0865
2022-05-26 2022-03-31 NP Corcept Therapeutics EC US2183521028 133,109 -15,435 -10.39 2,998 1.90 0.0698
2022-02-25 2021-12-31 NP Corcept Therapeutics EC US2183521028 148,544 0 0.00 2,941 0.62 0.0638
2021-11-24 2021-09-30 NP Corcept Therapeutics EC US2183521028 148,544 1,553 1.06 2,923 -9.59 0.0644
2021-08-26 2021-06-30 NP Corcept Therapeutics EC US2183521028 146,991 -831 -0.56 3,234 -8.05 0.0694
2021-05-27 2021-03-31 NP Corcept Therapeutics EC US2183521028 147,822 -3,270 -2.16 3,517 -11.03 0.0798
2021-02-25 2020-12-31 NP Corcept Therapeutics EC US2183521028 151,092 -4,753 -3.05 3,953 45.72 0.1013
2020-11-25 2020-09-30 NP Corcept Therapeutics EC US2183521028 155,845 -5,393 -3.34 2,712 0.00 0.0870
2020-08-27 2020-06-30 NP Corcept Therapeutics EC US2183521028 161,238 -504 -0.31 2,712 41.03 0.0886
2020-06-01 2020-03-31 NP Corcept Therapeutics EC US2183521028 161,742 12,786 8.58 1,923 6.71 0.0786
2020-02-27 2019-12-31 NP Corcept Therapeutics EC 218352102 148,956 1,375 0.93 1,802 -13.61 0.0542
2019-11-27 2019-09-30 NP Corcept Therapeutics EC US2183521028 147,581 147,581 2,086 0.0690
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.